Sharps Technology (NASDAQ:STSS) vs. MacroGenics (NASDAQ:MGNX) Head-To-Head Comparison

Sharps Technology (NASDAQ:STSS) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Sharps Technology and MacroGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sharps Technology	N/A	-84.26%	-79.52%
MacroGenics	-59.46%	-98.30%	-30.28%

Volatility and Risk

Sharps Technology has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Insider and Institutional Ownership

17.2% of Sharps Technology shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 1.2% of Sharps Technology shares are owned by insiders. Comparatively, 13.0% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Sharps Technology and MacroGenics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sharps Technology	$306,344.00	226.66	-$9.30 million	($831.83)	0.00
MacroGenics	$126.00 million	0.69	-$66.97 million	($1.20)	-1.14

Sharps Technology has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sharps Technology and MacroGenics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sharps Technology	1	0	0	0	1.00
MacroGenics	1	3	1	2	2.57

MacroGenics has a consensus price target of $3.60, indicating a potential upside of 162.77%. Given MacroGenics’ stronger consensus rating and higher probable upside, analysts clearly believe MacroGenics is more favorable than Sharps Technology.

Summary

MacroGenics beats Sharps Technology on 9 of the 15 factors compared between the two stocks.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

About MacroGenics

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.